COVID-19 vaccination centre in Cologne

Packages and a vial of AstraZeneca's COVID-19 vaccine are presented for a pictures at a vaccination centre, temporarily set up in a hall of the fair, amid the coronavirus disease pandemic in Cologne, Germany, March 18, 2021. REUTERS/Thilo Schmuelgen HEALTH-CORONAVIRUS/GERMANY

18-03-2021THILO SCHMUELGEN

The EU's drug watchdog said this evening it is still convinced the benefits of AstraZeneca's COVID-19 vaccine outweigh the risks following an investigation into reports of blood disorders that prompted more than a dozen nations to suspend its use.

The news came as the European Medicines Agency (EMA) director Emer Cooke said the agency could not definitively rule out a link to blood clot incidents and the vaccine in its investigation into 30 cases of a rare blood clotting condition.

It will however update its guidance to include an explanation about the potential risks for doctors and the public, she said.

The agency has been under growing pressure to clear up safety concerns after a small number of reports in recent weeks of bleeding, blood clots and low platelet counts in people who have received the shot.

The agency's review covering 5 million people, included 30 cases of unusual blood disorders in people in the European Economic Area (EEA), which links 30 European countries.

The EMA's focus and primary concern has been on cases of blood clots in the head, a rare condition that's difficult to treat called cerebral venous thrombosis (CVT) or a subform known as cerebral venous sinus thrombosis (CVST).

More than 45 million of the shots have been administered across the EEA.

At least 13 European countries, including France, Germany and Italy, have stopped administering the shot pending the review.

Britain's medicines regulator said today it was investigating five cases of CVST among people given AstraZeneca's vaccine but it reaffirmed that the benefits of the shot far outweighed any possible risks.

The World Health Organization also this week reaffirmed its support for the shot.
AstraZeneca has said a review covering more than 17 million people who had received its shots in the EU and Britain had found no evidence of an increased risk of blood clots.
Many governments have said the decision to pause inoculations was out of an abundance of caution.

But experts have warned the political interference could undermine public confidence and hobble the bloc's slow vaccination campaign as governments struggle to tame more infectious variants.

The bloc's vaccine roll-out has lagged the United States and former EU member Britain.

Comments

To be able to write a comment, you have to be registered and be logged in.

* Mandatory fields

Currently there are no comments.